百曜科技发起，《AI虚拟细胞（AIVC）技术趋势、产业生态与应用前景研究报告》正式发布

TL;DR - Baiyao Technology launched an industry report positioning AI virtual cells as reusable infrastructure for simulating cellular responses in drug discovery and life-science research. It argues that commercialization will depend less on model scale alone and more on integrated data, modeling, and experimental-validation capabilities.

• AIVC aims to create computational “digital mirrors” of cells that predict responses to interventions such as gene knockouts, drugs, and environmental changes.
• The report highlights generalization and task adaptation—not just parameter or dataset growth—as key model-development priorities, including world-model and JEPA-style approaches to cell-state transitions.
• High-quality proprietary perturbation, clinical, time-series, and multimodal data are presented as strategic advantages over public datasets.
• Industrial adoption requires a closed loop spanning data generation, model prediction, wet-lab validation, and experimental feedback; Baiyao cites applications including patient stratification, CAR-T optimization, and anti-aging target discovery.